Cumulatively, the results of mutation screening studies indicate that BRAFV600E is important to multiple pediatric glioma types, and suggest that this oncogenic alteration cooperates with CDKN2A deletion to promote neoplastic transformation and tumor malignant progression. This evidence concerns the gene CDKN2A and neoplasm.